Jan 30, 2026
Professional Article
Essential Thrombocythemia vs Polycythemia Vera: Understanding MPNs
Learn MoreJan 23, 2026
Newsroom
The U.S. NCCN Guidelines Included Ropeginterferon alfa-2b-njft (P1101) as a Recommended Treatment Option for Patients with Essential Thrombocythemia (ET)
Learn MoreJan 22, 2026
Professional Article
Hereditary Erythrocytosis: Primary and Secondary Forms Explained
Learn MoreJan 13, 2026
Newsroom
FDA Confirms a PDUFA Goal Date of August 30, 2026 for the sBLA Submission of Ropeginterferon Alfa-2b-njft in Essential Thrombocythemia (ET)
Learn MoreJan 12, 2026
Newsroom
PharmaEssentia Announces Positive Topline Phase 2b Data from EXCEED-ET Study Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia
Learn MoreDec 24, 2025
Newsroom
PharmaEssentia USA Announces Appointment of Jeffrey Williams as Independent Director
Learn MoreNov 25, 2025
Newsroom
PharmaEssentia Announces Publication of Phase 3 SURPASS-ET Results in The Lancet Haematology
Learn MoreNov 11, 2025
Newsroom
PharmaEssentia USA Announces Appointment of Dr. Barry Flannelly as Independent Director
Learn More